within Pharmacolibrary.Drugs.ATC.P;

model P01AB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 1.15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,
    adminCount     = 1,
    Vd             = 0.0516,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0038333333333333336,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Secnidazole is a nitroimidazole antimicrobial agent primarily used for the treatment of protozoal infections including amoebiasis, giardiasis, and trichomoniasis. It is similar to metronidazole but has a longer half-life, enabling single-dose oral therapies. Secnidazole is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects (both sexes, mean age ~27 years) after administration of a single oral dose.</p><h4>References</h4><ol><li><p>Mergenhagen, KA, et al., &amp; Russo, TA (2020). Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions. <i>Antimicrobial agents and chemotherapy</i> 64(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02167-19&quot;>10.1128/AAC.02167-19</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31871085/&quot;>https://pubmed.ncbi.nlm.nih.gov/31871085</a></p></li><li><p>Lamp, KC, et al., &amp; Lacy, MK (1999). Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clinical pharmacokinetics</i> 36(5) 353–373. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199936050-00004&quot;>10.2165/00003088-199936050-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10384859/&quot;>https://pubmed.ncbi.nlm.nih.gov/10384859</a></p></li><li><p>Zhu, DQ, et al., &amp; Chen, J (2007). Evaluation of the bioequivalence and pharmacokinetics of two formulations of secnidazole after single oral administration in healthy volunteers. <i>Arzneimittel-Forschung</i> 57(11) 723–726. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296674&quot;>10.1055/s-0031-1296674</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18193695/&quot;>https://pubmed.ncbi.nlm.nih.gov/18193695</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end P01AB07;
